October 2016

New Product - Tagrisso

Tagrisso (osimertinib mesilate) is an orally administered tyrosine kinase inhibitor (TKI). It is a selective and irreversible inhibitor of epidermal growth factor receptors (EGFRs) harbouring single (L858R or del746‑750) or double (L858R/T790M or del746‑750/T790M) mutations. Tagrisso is indicated for the treatment of patients with locally advanced or metastatic EGFR T790M mutation positive nonsmall cell lung cancer. This indication is approved on the basis of tumour response rate and duration of response. A confirmatory study assessing improvement in progression free survival and disease related symptoms is ongoing. Tagrisso is available as 40 mg and 80 mg tablets packed in a blister strip in cartons of 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629